CSLLY

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne